Drug-eluting stent coatings

Ma, Xiaodong; Wu, Tingting; Robich, Michael P.

doi:10.2217/ica.11.88

Cited by 32 publications

(33 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug eluting stent (DES) has established for the treatment for coronary artery disease (CAD) over the past decade by effectively reducing in-stent restenosis and for the target vessel revascularization (TVR) [3] [4] [5]. Despite that, some adverse events of durable polymers which were used in first-generation DES such as inflammation, vascular hypersensitivity reaction, neo-atherosclerosis, late and very late stent thrombosis (ST) were observed in extensive research [6] [7] [8].…”

Section: Introductionmentioning

confidence: 99%

“…Despite that, some adverse events of durable polymers which were used in first-generation DES such as inflammation, vascular hypersensitivity reaction, neo-atherosclerosis, late and very late stent thrombosis (ST) were observed in extensive research [6] [7] [8]. Consequently, several clinical studies have conducted and addressed the above mentioned adverse events through alteration of the stent platforms with blood and tissue compatibility, outer layer of the stent surface, effective antirestenosis drug, and polymer carriers [5] [9] [10]. Likewise, there remains concern about the inflammatory responses even though some non-biodegradable polymer-coated drug eluting stent pronounced to be safe for long term [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

Rao¹,

Rao²,

Kapardhi³

et al. 2017

WJCD

View full text Add to dashboard Cite

Background and Aim: Newer generation coronary stent systems with low profile metallic frame, biodegradable polymer coating and potent but safe anti-restenosis drug from "limus family" are emerging as safe and effective stents. To evaluate the safety and performance of Metafor SES (Meril life Sciences Pvt. Ltd., Vapi, India) in consecutive patients in a real-world population. Methods: The study was a retrospective, non-randomized, single-center study which evaluated the data of 127 patients who underwent percutaneous coronary intervention (PCI) treated with Metafor SES from February 2012 to February 2015 and mean follow-up period of those patients was 3.6 ± 0.6 years. The primary endpoint was a major adverse cardiac event (MACE) including cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR). In addition, Stent thrombosis (ST) was analyzed at respective follow-up period. Results: A total of 127 patients (mean age: 53.70 ± 8.41 years and 99 males) were included. Among those 80 (63%) patients had hypertension and 58 (45.7%) patients with diabetes mellitus.At follow-up, MACE in form of TLR was observed in 2 (1.6%) patients only. No cardiac death or stent thrombosis was reported in any patient. A total of 169 lesions were treated with the Metafor SES (1.3 stents per lesion). The 38.4% of patients treated with the Metafor SES with lesion length ≥24 mm, and the procedural success was 100%. Conclusions: The lower incidence of MACE in uncontrolled and real world population at long term follow-up clearly depicts the prolonged safety and performance of the Metafor SES.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

Rao¹,

Rao²,

Kapardhi³

et al. 2017

WJCD

View full text Add to dashboard Cite

show abstract

“…This standard nonsurgical treatment is effective in relieving the symptoms of coronary ischemia [3]. However, there are also some limitations for coronary stenting such as bare-metal stents, which may result in in-stent restenosis (ISR) due to the formation of scar tissues over the stent [4]. ISR doubles the risk of coronary ischemia and repeat revascularisation.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention: A Randomised Controlled Clinical Trial

Wang

Yang

Chu

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI). Ninety patients with UAP after PCI were randomly and equally assigned to three groups: the XFZY group, the SM group, and the placebo group, with 30 patients in each group. Six syndrome factors (including Qi deficiency, yin deficiency, yang deficiency, blood stasis, phlegm, and Qi stagnation) and 4 inflammatory markers (high-sensitivity C-reactive protein (Hs-CRP), endothelins-1 (ET-1), matrix metalloproteinases-9 (MMP-9), and homocysteine (Hcy)) were observed at week 0 and at the 1st, 4th and 12th weeks. In conclusion, the evolution of syndromes present in patients with UAP after PCI followed these trends (1) The deficiency syndromes gradually increased during a 12-week period, but the excess syndromes first gradually decreased and then mildly increased after PCI. (2) XFZY and SM can prevent excess syndromes from increasing in the later stages and prevent deficiency syndromes from increasing in all stages. (3) XFZY and SMcan reduce the levels of the inflammatory markers, especially in the later stages after PCI.

show abstract

“…The purpose of the micropores is to act as a reservoir for the drug and also to aid adhesion to the stent surface. The rough surface may be created by, for example, a sandblasting technique (Yukon stent, Translumina), or by a microabrasion process (BioFreedom stent, Biosensors Inc.) [23,22]. The VESTAsync stent (MIV Therapeutics) uses a hydroxyapatite surface coating [22].…”

Section: Introductionmentioning

confidence: 99%

“…These stents have the advantage of allowing for a higher drug loading capacity. The Optima stent (CID) contains nanopores too, but the pores are arranged in a regular slotted tubular fashion [23]. Fig.…”

Section: Introductionmentioning

confidence: 99%

Some design considerations for polymer-free drug-eluting stents: A mathematical approach

McGinty

Meere

et al. 2015

Acta Biomaterialia

View full text Add to dashboard Cite

In this paper we provide the first model of drug elution from polymer-free arterial drug-eluting stents. The generalised model is capable of predicting drug release from a number of polymer-free systems including those that exhibit nanoporous, nanotubular and smooth surfaces. We derive analytical solutions which allow us to easily determine the important parameters that control drug release. Drug release profiles are provided, and we offer design recommendations so that the release profile may be tailored to achieve the desired outcome. The models presented here are not specific to drug-eluting stents and may also be applied to other biomedical implants that use nanoporous surfaces to release a drug.

show abstract

Drug-eluting stent coatings

Cited by 32 publications

References 88 publications

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention: A Randomised Controlled Clinical Trial

Some design considerations for polymer-free drug-eluting stents: A mathematical approach

Contact Info

Product

Resources

About